BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31056957)

  • 21. Reduced tumorigenicity and drug resistance through the downregulation of octamer-binding protein 4 and Nanog transcriptional factor expression in human breast stem cells.
    Huang ZJ; You J; Luo WY; Chen BS; Feng QZ; Wu BL; Jiang L; Luo Q
    Mol Med Rep; 2015 Mar; 11(3):1647-54. PubMed ID: 25405855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.
    Croker AK; Allan AL
    Breast Cancer Res Treat; 2012 May; 133(1):75-87. PubMed ID: 21818590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2α.
    Kim RJ; Park JR; Roh KJ; Choi AR; Kim SR; Kim PH; Yu JH; Lee JW; Ahn SH; Gong G; Hwang JW; Kang KS; Kong G; Sheen YY; Nam JS
    Cancer Lett; 2013 Jun; 333(1):18-31. PubMed ID: 23174107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stem cells: their role in breast cancer development and resistance to treatment.
    Nicolini A; Ferrari P; Fini M; Borsari V; Fallahi P; Antonelli A; Berti P; Carpi A; Miccoli P
    Curr Pharm Biotechnol; 2011 Feb; 12(2):196-205. PubMed ID: 21044007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer.
    Lanzardo S; Conti L; Rooke R; Ruiu R; Accart N; Bolli E; Arigoni M; Macagno M; Barrera G; Pizzimenti S; Aurisicchio L; Calogero RA; Cavallo F
    Cancer Res; 2016 Jan; 76(1):62-72. PubMed ID: 26567138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
    Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Pinzòn-Daza ML; Giordano A; Desiderio V; Ghigo D; De Rosa G; Caraglia M; Riganti C
    Oncotarget; 2016 Apr; 7(15):20753-72. PubMed ID: 26980746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
    Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
    Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.
    Ruiu R; Rolih V; Bolli E; Barutello G; Riccardo F; Quaglino E; Merighi IF; Pericle F; Donofrio G; Cavallo F; Conti L
    Cancer Immunol Immunother; 2019 Jan; 68(1):131-141. PubMed ID: 29947961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells.
    Sun R; Shen S; Zhang YJ; Xu CF; Cao ZT; Wen LP; Wang J
    Biomaterials; 2016 Oct; 103():44-55. PubMed ID: 27376558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.
    Thiagarajan PS; Hitomi M; Hale JS; Alvarado AG; Otvos B; Sinyuk M; Stoltz K; Wiechert A; Mulkearns-Hubert E; Jarrar A; Zheng Q; Thomas D; Egelhoff T; Rich JN; Liu H; Lathia JD; Reizes O
    Stem Cells; 2015 Jul; 33(7):2114-2125. PubMed ID: 25827713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ALDH1⁺ subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics.
    Li D; Zhang T; Gu W; Li P; Cheng X; Tong T; Wang W
    Oncol Rep; 2015 May; 33(5):2291-8. PubMed ID: 25760144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy.
    Paholak HJ; Stevers NO; Chen H; Burnett JP; He M; Korkaya H; McDermott SP; Deol Y; Clouthier SG; Luther T; Li Q; Wicha MS; Sun D
    Biomaterials; 2016 Oct; 104():145-57. PubMed ID: 27450902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo monitoring of CD44+ cancer stem-like cells by γ-irradiation in breast cancer.
    Kim MH; Kim MH; Kim KS; Park MJ; Jeong JH; Park SW; Ji YH; Kim KI; Lee TS; Ryu PY; Kang JH; Lee YJ
    Int J Oncol; 2016 Jun; 48(6):2277-86. PubMed ID: 27098303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of the target proteins in chemotherapy resistant breast cancer stem cell-like cells by protein array.
    Kars MD; Yıldırım G
    Eur J Pharmacol; 2019 Apr; 848():23-29. PubMed ID: 30707960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
    Koziel JE; Herbert BS
    Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
    Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
    Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer stem-like cells can promote metastasis by activating platelets and down-regulating antitumor activity of natural killer cells.
    Wang S; Zhang Y; Cong W; Liu J; Zhang Y; Fan H; Xu Y; Lin H
    J Tradit Chin Med; 2016 Aug; 36(4):530-7. PubMed ID: 28459521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
    Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
    Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
    Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
    Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vivo Anti-Tumor Effects of Citral on 4T1 Breast Cancer Cells via Induction of Apoptosis and Downregulation of Aldehyde Dehydrogenase Activity.
    Nigjeh SE; Yeap SK; Nordin N; Rahman H; Rosli R
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31492037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.